Our Products and Product Candidates

Immuron has a pipeline of eight products and product candidates that range from early stage research to on-the-market products. All of these products are based on the same platform and are thus expected to have a high safety profile.

The products arising from our platform are eligible for obtaining marketing approval from the Food and Drug Administration (FDA) in the US and analogous regulatory authorities in other jurisdictions, through submitting an Investigational New Drug (IND) application or corresponding application in other jurisdictions. If approved, Immuron’s products can be sold as prescription only medications and/or can also be developed as over the counter (OTC) medications. Since the key factors for success in both development routes is safety and efficacy and our products have a well established safety profile, there is a prospect that the clinical development of Immuron’s products will be expedited.